#AI #Health #Stock News: GBT (OTCPINK: $GTCH) Continues Research on AI Detection System

 #AI #Health #Stock News: GBT (OTCPINK: $GTCH) Continues Research on AI Detection System

 

SAN DIEGO - January 7, 2021 (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT", or the "Company"), announced that its joint venture, GBT Tokenize Corp. ("GBT/Tokenize"), is continuing with its research associated with an AI system to detect and open clogs within arteries based on its proprietary radio technology, which has an internal code name of "Hermes".

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01071AI-Detection-System.asp 

 

The research is evaluating a system targeted for arterial clogs cleaning, such as a coronary artery, peripheral artery, or any other body vascular organ. The researching is focusing on the use of an intravenous mini-probe unit that could travel within the artery, searching to find clogs including complete blockages (Total Occlusions). Upon detecting a clog, GBT/Tokenize will evaluate whether the system will have the capability to remove it and clear the blood vessel for efficient blood flow. This blockage may cause a condition called atherosclerosis (when a substance called plaque builds up in the walls of the arteries) and can eventually block the artery, causing vascular disease, heart attack or stroke. The research is evaluating whether the unit can use AI based and radio frequency imaging system to "see" within arteries. We are now researching the development of a low frequency radio system to scan within arteries, producing 3D visuals, shown on a computer screen, and used for intravenous navigation.

 

GBT/Tokenize is evaluating developing a system that will have the capability to be manually remote controlled by physicians or to autonomously operated inside blood vessels. It is intended that an advanced SOC (System on Chip) microchip with an embedded software will control the unit's operations. The goal is to research the inclusion of a wireless communication capability to produce a computerized 3D imaging for the operating physician. We are evaluating initial setup of the system for inserted into a human body, for example through a large leg artery, and autonomously or manually travel further to other parts of the body. Using a variety of micro-sensors, we are researching the viability of a system that will search and remove clogs without damaging the vessel's tissue. The device is intended to use an innovative AI controlled propulsion system that is based on water jet propulsion concept that does not involve external, rotating moving parts to avoid artery's walls damages. This research is looking into the viability of the use of the most recent micromachining mechanical engineering technology.

 

"Our AI technology can be implemented in a wide variety of applications to control mechanical, optical and electrical systems, analyzing arterial data and making decisions in real time. We are commencing research - code name Hermes, to use our AI capabilities to search, identify and remove plaque within arteries and blood vessels. In this project, we are researching the ability to use GBT Tokenize's AI technology to control a mini-probe unit that will be inserted into a human body through a main artery. If our research is positively concluded, we believe that this type of system can be a breakthrough within the cardiovascular domain, offering less invasive treatments and introducing a new method to save lives. Artificial Intelligence technology encapsulates the future health care and we're investing vast efforts to utilize our experience and knowledge in this domain."

 

If the research of the device is successfully concluded, the Company will be required to obtain approval for use of the device from the US Food and Drug Administration ("FDA"). Further, following the conclusion of the research, the development of this product would require significant funds as well as the partnering with a company that specializes in the development of medical devices and obtaining FDA approval.

 

About Us

 

GBT Technologies, Inc. (OTC PINK: GTCH) ("GBT") (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT's mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT's goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT's vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

#MedicalTechnology #Stock Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles; @Sigyn_inc

 #MedicalTechnology #Stock Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles; @Sigyn_inc

 

Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions That Are Not Addressed with Drug Therapies

 

SAN DIEGO CA, January 6, 2021 -- (Investorideas.com Newswire) Medical Therapeutic technology stock news - Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) , a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream. 

 

Read this news, featuring SIGY in full at https://www.investorideas.com/news/2021/biotech/01061SIGY-Inflammatory-CytoVesicles.asp

 

Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death.  The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide.  Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.

 

Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions.  Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include pro-inflammatory cytokines, endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) that participate in concert with freely circulating cytokines to further escalate the Cytokine Storm.   CytoVesicles are an important yet previously elusive target as they can be 20-60 times larger than cytokines themselves. 

 

In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma.  After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%.  Previously published studies have validated liposomes as a model for the isolation of  extracellular vesicles from blood based on the similarity of their size and structural characteristics.

 

“When we designed Sigyn Therapy, we envisioned a device that could be broadly deployed by the medical community, yet also have expansive first-in-industry capabilities that offer to improve patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When considering our previous report that Sigyn Therapy™ clears both endotoxin and inflammatory cytokines from human blood plasma, the observation from our CytoVesicle pilot study further reinforces the potential for our vision to become a therapeutic reality.”

 

Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of an in vitro study that validated the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

 

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.  

 

The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.

 

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

 

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

 

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

 

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

jj@sigyntherapeutics.com

 

Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure : this news release featuring Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), is a paid for service on Investorideas.com . More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com lease read Investorideas.com privacy policy https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com

https://www.investorideas.com/About/

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

 

 

#AI #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) is Developing Advanced Computational Geometry Methods

 #AI #Health #Stock News: GBT Tokenize (OTCPINK: $GTCH) is Developing Advanced Computational Geometry Methods

 

San Diego, CA, January 5, 2021 – (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT”, or the “Company”), announced that GBT Tokenize (“GBT/Tokenize) is developing new methods for health analysis based on its Kirlian Electrophotography research. GBT/Toeknize is developing a set of methods and algorithms to analyze imaging made by Kirlian Electrophotography.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2021/01051Computational-Geometry-Methods.asp

 

Kirlian photography introduces a series of techniques that are based on the phenomenon known as electrical coronal discharge. Images that are produced using these techniques present a colorful so-called aura. Although not scientifically proven, some believe that these images can be interpreted to analyze health conditions. GBT/Tokenize reiterates that the claim that a medical conclusion can be reached based on analysis of the image (whether through AI or in person) has not been scientifically established. GBT/Tokenize is performing open research from a technological point of view, which cannot be considered medical research or portrayed to be as such.

 

It is believed by some that the Kirlian imaging process is made by placing an object on a photographic plate that is connected to a source of high-voltage current. A more modern way is using low voltage hand and head sensors to produce visual, interactive data that may represent health energy information. Kirlian imaging can produce organs energetic visualization such as graphical protuberances, halos, and discharge patterns, which can be analyzed by computer program to identify unique patterns. GBT is now developing a set of computational geometry algorithms targeted to be the base for a further AI analysis. Computational geometry is a mathematical field that involves the design, analysis and implementation of efficient algorithms for solving geometric problems. Advanced applications that typically use computational geometry methods are pattern recognition, computer vision, animation and graphics, (CAD) computer-aided design, robotics, and similar especially when require real-time speeds. We are developing a private, derived set of algorithms in order to classify the combinatorial and numerical computational geometry of Kirlian images. Each set is designed to identify, analyze and categorize images according to its parametric surfaces and curves, for example, spline curves and Bezier curves. This information will be fed to a machine learning program. Our algorithms are identifying and evaluating the image's surfaces and parts of surfaces from particular viewing angles in order to categorize and classify anomalies.  

 

"Kirlian imaging of living tissue may exhibit energy levels that can be visualized as auras. We are now developing a set of geometrical computation methods and algorithms to graphically analyze these images further feeding the data into our machine learning programs. The target is to reach consistent and reliable conclusions with respect to the analysis of the image and any anomalies.  Computational geometry is a field of computer science that is aimed to solve problems stated in terms of geometry. Here we are implementing these techniques for Kirilian images to find unique patterns. The development of these geometrical algorithms is part of our image processing long term plan and will be further used during next year for AI imaging analytics. For example, we develop a specific version of Scanline method which is an algorithm that typically works on a row-by-row basis rather pixel-by-pixel basis. We created a new flow to identify critical vertexes only and then analyze pixel-by-pixel. This enables light speed image analysis in order to search and classify image's points of interest. The main advantage of our version is that the sorting of crucial vertices only, is done in parallel with the normal scan, significantly shortening the overall scan time and reducing objects-of-interest detection time. We develop plane sweep based algorithms that works via a conceptual sweep line to analyze Kirilian images as an infrastructure for our AI program. The main idea is to scan across the image, stopping at object of interest vertexes (points) to identify patterns and consistencies. These geometric operations will become geometric objects that will intersect with others to form a human organ aura. By looking for full and partial similarities, repetitions, or atypical auras patterns, our goal is to be able to detect dynamic images changes in time. In addition, another set of computational geometry algorithms will search object's boundaries in order to detect specific patterns and finding images correlations. The geometrical computation engine will be the first step to extract the base data from the Kirilian images and later processed by the AI engine. " 

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements".  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

 

 

#AI #Health Breaking News: GBT Tokenize (OTCPINK: $GTCH) is Developing a Private, Advanced #Security Protocol, qNET For qTerm

 #AI #Health Breaking News: GBT Tokenize (OTCPINK: $GTCH) is Developing a Private, Advanced #Security Protocol, qNET For qTerm

 

SAN DIEGO - December 29, 2020 (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT", or the "Company"), announced that its Joint Venture, GBT Tokenize Corp ("GBT/Tokenize"), is developing a new security protocol, code name qNET, for its qTerm vital device.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2020/12291qNET.asp

 

As qTerm device will be communicating through a mobile application with a backend program, transferring private information, a secured network protocol is needed to set the rules and conventions for communication between the network devices. The protocol includes methods for node's identification, packet exchange and formatting rules. GBT is developing a highly secured protocol based on its database sharing technology. In this method, a communication message is done using a packet's segmentation technique. The segments are sent to many nodes as an index algorithm maintains locations, segment's size and other essential packet's information. In addition, it ensures redundancy to keep message reliability. GBT has already developed a gNET security system in order to protect high and low level networks, in addition to wireless communication. qNET is a private derivative of gNET private, secured protocol that will be adopted for qTerm communication. qNET protocol will have a security policy that is supervised by GBT's AI system. The security policy is designed to provide high-level security principles in order to maintain user's privacy and keep personal data confidential. The policy also defines the protocol's encryption algorithms that will be used. With the goal of achieving a high security level, the protocol will be compliant with the National Institute of Standards and Technology's security and privacy guidelines, as stated in NIST 800-53 publication. NIST 800-53 guidelines recommend security policies and procedures for federal information and organizations and were also adopted by the private sector. The NIST is a non-regulatory agency of the U.S. Commerce Department and was established to encourage and assist innovation and science through the promotion and maintenance of a set of industry standards and guidelines.

 

These guidelines were created to heighten the security of the information systems used within the federal government. GBT's qNET security protocol will be multi-tiered based and self monitored by a machine learning algorithm. The system is based on Zero Trust network security model which is based on a strict identity verification process. This model dictates authentication and authorization to access the application's data. At the same time, it is designed to protect users from advanced threats that may occur through the Internet. qNET protocol is planned to be fully equipped with a high security encryption algorithm called AES 256. AES (Advanced Encryption Standard) was developed to meet the needs of the U.S. Government and is one of the most trusted security algorithms that is used by the U.S. Government and private corporations. Another layer of encryption will be the Honey Encryption method which targets to deceive hackers by providing them with a fake information any time an incorrect password or encryption key is guessed as part of a malicious attack. The complete qNET system is planned to be developed by the end of the year 2021.

 

"qTerm vital device will be using private and confidential users information and it is our highest priority to protect it. That is why we are investing in the development of qNET, a dedicated, private network security protocol, especially designed for qTerm. qNET will include a high and low level security protocol since it is planned to be used for communication over the internet. Within qNET we are adopting government security standards, guidelines and high levels of encryption technology. We are going to use our database sharing segmentation methods according to the recent patent that was granted by the USPTO earlier this month. The data will be split into segments and stored on numerous network nodes. Each segment is meaningless by itself and only by assembling them together, as part of a huge puzzle, the information is revealed. Each segment is encrypted to further heighten its security. In order to protect user's data from malicious cyber attacks an AI system will be constantly monitoring the overall network 24/7. In case of a breach the system will take an immediate action by closing chosen network's nodes and re-locating the data to alternative devices according to redundancy plan. Since we have few types of networks, we plan to use AES 256 and honey encryption methods to ensure the highest security. Network security is probably one of the most popular fields nowadays due to the vast amount of information that is at risk. Therefore, we will spare no expense with the development of qNET to provide operational, technical, and AI controlled safeguards to maintain the integrity, confidentiality, and security of qTerm users' information. The system is planned to be completed by the end of next year and will work with qTerm's mobile application, backend and a web based interface over the internet," stated Danny Rittman, GBT's Chief Technology Officer.

 

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) ("GBT") (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT's mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT's goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT's vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
GBT Technologies Inc.
Media: press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories

 

 

 

#AI #Health Breaking News: GBT (OTCPINK: $GTCH) is Developing an AI Based Graphics Analytics System; #Artificialintelligence

 #AI #Health Breaking News: GBT (OTCPINK: $GTCH) is Developing an AI Based Graphics Analytics System; #Artificialintelligence

 

SAN DIEGO - December 22, 2020 (Investorideas.com Newswire) GBT Technologies Inc. (OTCPINK: GTCH) ("GBT", or the "Company"), is developing an AI based graphic analytics system, targeted for medical imaging. As part of the company's plan to move forward towards the medical analytics field, we started research and development activities to seek and improve detection of diseases and symptoms using computer vision analysis.

 

Read this news, featuring GTCH in full at https://www.investorideas.com/CO/GOPH/news/2020/12221AI-Graphics-Analytics.asp

 

The efforts are invested into AI applications to detect and interpret medical images, like MRI, X-Ray, CT, PET and Ultrasound, with the goal of helping guiding physicians in capturing possible issues within scans of human organs. The project's internal name is "Imaging Predictive Analytics" (IPA) and it targets to analyze, alert and predict potential issues based on graphical data. We are focusing on getting the most value of our AI analytics power for images and scans of high resolution. The project is targeting the development of analysis technologies that can be used for biomedical purposes. For example, the aim of the IPA system is to be an added system to assist physicians with real time ultrasound scan to alert of potential suspicious findings that may be too small or unclear for the human eye. Another potential implementation would be to analyze MRI, CT and PET images to search and alert physicians for abnormalities. Medical images include high resolution data and the IPA system aims to automate the detection of abnormalities in commonly-ordered imaging in order to lead to quicker decision-making with the goal of reducing diagnostic errors in a wide variety of medical fields. One of these potential implementations is the cardiovascular field. Analyzing images to measure various structures of the heart can reveal risks for onset cardiovascular diseases or identify other abnormalities that may need to be addressed through surgery or medications. Another field is the respiratory area. This domain requires fast medical response in order to assist with respiratory therapy for patients with cardiopulmonary (heart/lung) illnesses and breathing difficulties, for example pneumonia and pneumothorax (Collapsed lung). It is our goal to use the IPA artificial intelligence based algorithms to provide for quick imaging analysis pointing physicians to provide the necessary treatment. The system is designed to incorporate deep learning methods and concepts that were initially developed within the company's Avant!-AI and Hipocrates system.

 

"According to our R&D plans 2021, we are moving forward to develop more advanced AI systems for the medical domain. Today's medical imaging consists of ultra high resolution scans that include numerous details. We started the development of our Imaging Predicting Analytics system, internal code name IPA, which we believe will be especially useful if fully developed when quick response is necessary. For example, in case of cardiovascular or respiratory conditions, a rapid imaging analytics may save lives by quickly finding anomalies that may be urgently addressed. The system is planned to have 2D and 3D simulation including rotations, cross sections and mapping. We already developed graphic analytics techniques within our Avant! AI system and now plan to further develop advanced deep learning imaging algorithms to analyze modern images of CT, MRI, X-RAY, PET and Ultrasound. We believe we will be able to target the system to assess images for evidence of abnormalities and alert providers to the potential diagnoses, with the goal of pointing subjects-of-interest to physicians, enabling faster treatment. The system is planned to use AI algorithms to learn the image parameters and train a neural network for pixels recognition and analytics. We intend for the the system to provide risk scores for areas of concern. We target to improve diagnostic's accuracy and potentially alert for risky factors, eliminating unnecessary tests and benign biopsies. We believe that medical imaging data is one of the richest sources of information, and one of the most complex ones. Artificial intelligence science has already proven to be an efficient assistant for radiologists and health professionals for the past decade, pursuing faster, more accurate, and comprehensive patient care. But our challenges are growing exponentially and so are our needs. 2D data is rapidly moving to 3D form, enabling better information representation in many medical fields. Today's imaging analytics complexity requires advanced computerized disciplines and a quantum leap approach in order to handle vast data, especially when real-time factor has become crucial. Our goal is to develop native graphic-rich disciplines to augment image analytics algorithms and flows, enabling better, and more accurate medicine and diagnostics."

 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements". Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

 

Contact:

Dr. Danny Rittman, CTO
GBT Technologies Inc.
Media: press@gopherprotocol.com

 

GBT Technologies Inc. (OTCQB:GTCH) is a featured tech stock on

Investorideas.com

 

More info on GTCH at Investorideas.com Visit: https://www.investorideas.com/CO/GOPH/

 

Get News Alerts on GBT Technologies Inc GTCH

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Disclosure: GTCH is a PR, social media and publishing client and compensates Investorideas.com https://www.investorideas.com/About/News/Clientspecifics.asp

Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

  Get more tech stocks investor ideas- news, articles, podcasts and stock directories